Weight-loss drugs show broad power to prevent and reduce addiction

Overview

Updated May 30

Drugs designed to control blood sugar and shrink waistlines may also quiet the cravings that drive addiction. A March 4 BMJ study of more than 600,000 U.S. veterans found GLP-1 users were 14 percent less likely to develop a new substance use disorder.

Among those who already had one, the drugs reduced substance-related deaths by 50 percent and overdoses by 39 percent. The effect was uniform across alcohol, opioids, cocaine, cannabis, and nicotine, suggesting GLP-1 medications act on the craving mechanism itself rather than on any single substance. If confirmed in randomized trials now underway, the medications could become the first broadly effective pharmacological tool against addiction, a field where treatment options have barely expanded in decades.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Play on this story Voices Debate Predict Timeline Connections

Key Indicators

606,434

Veterans studied

Electronic health records of U.S. veterans with type 2 diabetes analyzed over three years

14%

Reduced risk of new substance use disorder

Overall reduction in risk of developing any new substance use disorder among GLP-1 users versus non-GLP-1 diabetes patients

50%

Fewer substance-related deaths

Reduction in drug-related deaths among people with existing substance use disorders who started GLP-1 treatment

25%

Reduced opioid addiction risk

GLP-1 users were 25 percent less likely to develop a new opioid use disorder, the largest reduction among individual substances

$63B+

Global GLP-1 market (2025)

Annual revenue of the GLP-1 receptor agonist market, projected to exceed $130 billion by 2035

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up

Predict 4 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Ziyad Al-Aly

Clinical epidemiologist, Washington University School of Medicine; Chief of Research and Development, VA Saint Louis Health Care System

Lead author of the March 2026 BMJ study

Nora Volkow

Director, National Institute on Drug Abuse (NIDA)

Advocating for expanded GLP-1 addiction research

Christian Hendershot

Researcher, University of North Carolina at Chapel Hill

Lead author of first randomized trial of semaglutide for alcohol use disorder

Organizations Involved

Novo Nordisk

Pharmaceutical company

Maker of Ozempic and Wegovy; not pursuing dedicated addiction trials

Danish pharmaceutical company that developed semaglutide and dominates the GLP-1 market with Ozempic (diabetes) and Wegovy (obesity).

Eli Lilly and Company

Pharmaceutical company

Actively pursuing GLP-1 addiction trials

American pharmaceutical company pursuing the most aggressive GLP-1 addiction research program among major drugmakers.

Washington University School of Medicine

Academic research institution

Published landmark BMJ study on GLP-1 and addiction

St. Louis-based medical school whose researchers produced the largest observational study linking GLP-1 drugs to reduced substance use disorders.

Timeline

January 1986 March 2026

10 events Latest: March 4th, 2026 · 6 months ago

Tap a bar to jump to that date

March 2026
Largest study finds GLP-1 drugs reduce addiction risk across all major substances
Latest Research

Washington University researchers publish a study of 606,434 veterans in The BMJ showing GLP-1 drugs are associated with a 14 percent lower risk of new substance use disorders and, for those already addicted, 50 percent fewer substance-related deaths and 39 percent fewer overdoses.
March 4th, 2026
December 2025
Eli Lilly announces large-scale addiction trials
Industry

Eli Lilly CEO David Ricks announces the company will begin large studies of GLP-1 drugs in alcohol and drug abuse, including phase 3 trials of brenipatide for alcohol use disorder.
December 1st, 2025
July 2025
Brown University researchers describe 'turning point in addiction psychiatry'
Research

Brown University researchers publish analysis framing GLP-1 drugs as a potential paradigm shift in addiction treatment, citing converging preclinical and clinical evidence.
July 24th, 2025
February 2025
First randomized trial shows semaglutide reduces alcohol consumption
Research

A phase 2 trial of 48 adults with alcohol use disorder, published in JAMA Psychiatry, finds that low-dose semaglutide reduces alcohol intake during lab sessions, craving, and heavy drinking days compared to placebo.
February 1st, 2025
March 2024
NIDA director calls GLP-1 addiction data 'very, very exciting'
Statement

Nora Volkow, director of the National Institute on Drug Abuse, publicly endorses the potential of GLP-1 drugs to treat addiction, lending high-level institutional support to the research direction.
March 21st, 2024
January 2022
Anecdotal reports of reduced cravings emerge
Observation

Patients and clinicians begin reporting that GLP-1 drugs suppress not just food cravings but also urges to drink alcohol, smoke, and use drugs, prompting researchers to investigate systematically.
January 1st, 2022
June 2021
Wegovy approved for weight management
Regulatory

The FDA approves a higher-dose version of semaglutide (Wegovy) for chronic weight management in adults, accelerating widespread use and the first wave of anecdotal reports about reduced cravings for alcohol and other substances.
June 4th, 2021
December 2017
Ozempic approved for diabetes
Regulatory

The Food and Drug Administration (FDA) approves Novo Nordisk's injectable semaglutide (Ozempic) for type 2 diabetes, the drug that will later become central to addiction research.
December 5th, 2017
April 2005
FDA approves first GLP-1 drug for diabetes
Regulatory

Exenatide (Byetta), derived from a compound found in Gila monster venom, becomes the first GLP-1 receptor agonist approved in the United States, initially for type 2 diabetes.
April 28th, 2005
January 1986
Scientists isolate GLP-1 from the gut
Discovery

Researchers identify truncated glucagon-like peptide-1, a gut hormone that stimulates insulin secretion and inhibits glucagon, laying the foundation for a new drug class.
January 1st, 1986

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

1948–1951

Disulfiram (Antabuse) and the limits of aversion therapy (1951)

Danish researchers discovered that disulfiram, a chemical used in rubber manufacturing, caused violent illness when combined with alcohol. The FDA approved it in 1951 as Antabuse, the first medication for alcohol dependence. It worked not by reducing craving but by making drinking physically punishing — nausea, vomiting, and flushing.

Then

Early adoption was enthusiastic. Ruth Fox, the founding president of the American Society of Addiction Medicine, treated about 2,500 patients and reported the drug was effective at deterring drinking.

Now

Compliance proved to be the fundamental problem: patients who wanted to drink simply stopped taking the pill. Disulfiram remains available but is rarely prescribed today, illustrating the limits of a deterrence-based approach to addiction that does not address the underlying craving.

Why this matters now

GLP-1 drugs represent the opposite pharmacological strategy. Instead of punishing consumption, they appear to reduce the craving that drives it. If confirmed, this would address the exact failure point that limited Antabuse's effectiveness for 75 years.

1984–1994

Naltrexone's expansion from opioids to alcohol (1984–1994)

The FDA approved naltrexone in 1984 to treat opioid addiction by blocking opioid receptors. A decade later, researchers discovered it also reduced alcohol cravings and heavy drinking, leading to a second FDA approval for alcohol use disorder in 1994. It was one of the first demonstrations that a drug targeting one addictive pathway could help with a different substance entirely.

Then

Naltrexone provided the first pharmacological option for alcohol use disorder that directly reduced craving rather than creating aversion.

Now

Despite proven efficacy, naltrexone remains underused due to stigma around medication-assisted addiction treatment and because it addresses only opioid and alcohol pathways, not the broader reward circuitry involved in other addictions.

Why this matters now

GLP-1 drugs may extend the naltrexone precedent much further. Where naltrexone crossed from one substance to a second, GLP-1 data suggests activity across all major substance classes, pointing to a more fundamental craving mechanism than the opioid receptor system alone.

January 1988

Prozac and the SSRI revolution (1988)

Eli Lilly launched fluoxetine (Prozac), the first selective serotonin reuptake inhibitor (SSRI), for depression. Within months it outsold every existing antidepressant. Doctors began prescribing it not just for major depression but for obsessive-compulsive disorder, bulimia, panic disorder, and anxiety — conditions for which it had not yet been formally approved.

Then

Prozac became a cultural phenomenon, selling $2.7 billion annually at its peak. Millions of people who would not have sought treatment for depression began taking medication.

Now

SSRIs eventually received FDA approvals for multiple conditions beyond depression, validating the off-label use that preceded formal regulatory action. The class demonstrated that a drug targeting one brain mechanism can treat a range of disorders sharing that underlying biology.

Why this matters now

GLP-1 drugs are following a strikingly similar trajectory: approved for one condition (diabetes), then a second (obesity), now showing broad effects on a third category (addiction) that shares underlying brain reward circuitry. The SSRI precedent suggests off-label prescribing may outpace formal approvals.